Hepatocellular transplantation in acute hepatic failure and targeting genetic markers to hepatic cells.
Orthotopic liver transplantation (OLT) represents the only therapeutic option for many patients with end-stage liver disease as well as many inborn genetic errors of hepatic metabolism. Despite dramatic progress in methods for OLT, the utilization of this procedure is limited by its considerable morbidity and mortality, by a chronic shortage of organs for transplant, and by difficulty arranging funding for many patients. Many children with fulminant hepatic failure do not receive OLT because this technology is unavailable or unaffordable. Hepatocellular transplantation (HCT), in which isolated, heterologous hepatocytes from a donor liver would be infused into the diseased organ in order to provide essential hepatic functions, could provide a much needed therapeutic alternative to OLT in the treatment of some causes of hepatic insufficiency. Experiments in animals have demonstrated that several genetic deficiencies of hepatic metabolism as well as experimental induced hepatic failure in animals can be reversed by HCT. Despite this experience, HCT has never been attempted in human subjects. This protocol represents the first proposed clinical trial of HCT. We are proposing a clinical trial in which HCT would be attempted as a therapeutic intervention in children with acute hepatic failure who have no other medical or surgical options. This proposal is intended to establish surgical methods for HCT and to evaluate the feasibility of this procedure for treating hepatic disease in humans. It is our expectation that HCT may provide short-term support for patients awaiting organ availability, a "bridge to recovery" allowing patients with fulminant hepatic failure to recover, or a long-term repopulation of the patient's liver with healthy donor cells. One of the major limitations of many animal studies in HCT is that, since the donor hepatocytes are often indistinguishable from those of the host, it has often been difficult to demonstrate a clear correlation between engraftment and the therapeutic effect. In order to verify engraftment independent of the therapeutic response, we propose to "mark" the donor hepatocytes by transducing these cells with a recombinant retroviral vector (LNL6) carrying a marker gene (NEO-R, neomycin phosphoribosyl transferase). The presence of this marker will enhance the ability to identify transplanted cells in the host using assays for the NEO-R gene or transcribed NEO-R mRNA. The LNL6 vector has been approved for human use and has been used as a marker gene for transplanted cells in human subjects without any reported adverse effects. We would like to emphasize that this is a proposal with therapeutic intent.(ABSTRACT TRUNCATED AT 400 WORDS)
Ledley
F D
FD
Baylor College of Medicine, Department of Cell Biology, Houston, TX.
Woo
S L
SL
Ferry
G D
GD
Whisennand
H H
HH
Brandt
M L
ML
Darlington
G J
GJ
Demmler
G J
GJ
Finegold
M J
MJ
Pokorny
W J
WJ
Rosenblatt
H
H
D000208:Acute Disease; D000818:Animals; D002985:Clinical Protocols / Q000592:standards; D002986:Clinical Trials as Topic; D004285:Dogs; D005240:Feasibility Studies; D005819:Genetic Markers; D005822:Genetic Vectors; D006085:Graft Survival; D006801:Humans; D007258:Informed Consent; D019868:Kanamycin Kinase; D008099:Liver / Q000166:cytology*; D008107:Liver Diseases / Q000473:pathology / Q000601:surgery*; D016031:Liver Transplantation / Q000379:methods*; D051379:Mice; D010770:Phosphotransferases / Q000032:analysis / Q000235:genetics; D016133:Polymerase Chain Reaction; D011994:Recombinant Proteins / Q000032:analysis / Q000235:genetics; D012190:Retroviridae; D014161:Transduction, Genetic
D005819:Genetic Markers; D011994:Recombinant Proteins; D010770:Phosphotransferases; D019868:Kanamycin Kinase